Publicações de autores portugueses
ÍNDICE
PUBLICAÇÕES SOBRE DOENÇAS DO ESPETRO DA NEUROMIELITE ÓPTICA
PROGNOSTIC FACTORS ASSOCIATED WITH DISABILITY IN A COHORT OF NEUROMYELITIS OPTICA SPECTRUM DISORDER AND MOG-ASSOCIATED DISEASE FROM A NATIONWIDE PORTUGUESE REGISTRY
Moura J, Samões R, Sousa AP, Figueiroa S, Mendonça T, Abreu P, Guimarães J, Melo C, Sousa R, Soares M, Correia AS, Brás Marques I, Perdigão S, Alves I, Felgueiras I, Nzwalo I, Mendes I, Almeida V, Boleixa D, Carneiro P, Neves E, Silva AM, Sá MJ, Santos E.
J Neur Sci 464 (2024) 123176. Doi: 10.1016/j.jns.2024.123176.
SEX RATIO AND AGE OF ONSET IN AQP4 ANTIBODY-ASSOCIATED NMOSD: A REVIEW AND META-ANALYSIS.
Arnett S, Chew SH, Leitner U, Hor JY, Paul F, Yeaman MR, Levy M, Weinshenker BG, Banwell BL, Fujihara K, Abboud H, Dujmovic Basuroski I, Arrambide G, Neubrand VE, Quan C, Melamed E, Palace J, Sun J, Asgari N, Broadley SA; Guthy Jackson International Clinical Consortium*.
J Neurol. 2024 Jul 3. doi: 10.1007/s00415-024-12452-8.
COGNITIVE IMPAIRMENT IN NEUROMYELITIS OPTICA SPECTRUM DISORDER: A RETROSPECTIVE STUDY USING THE BRIEF INTERNATIONAL COGNITIVE ASSESSMENT FOR MULTIPLE SCLEROSIS (BICAMS).
Lopes C, Sousa C, Fraga A, Guimarães J, Vicente S, Sá MJ.
Appl Neuropsychol Adult. 2023 May 17:1-7. doi: 10.1080/23279095.2023.2210242.
LATE ONSET NEUROMYELITIS OPTICA SPECTRUM DISORDERS (LONMOSD) FROM A NATIONWIDE PORTUGUESE STUDY: ANTI-AQP4 POSITIVE, ANTI-MOG POSITIVE AND SERONEGATIVE SUBGROUPS.
Santos E, Moura J, Samões R, Sousa AP, Mendonça T, Abreu P, Guimarães J, Correia I, Durães J, Sousa L, Ferreira J, de Sá J, Sousa F, Sequeira M, Correia AS, André AL, Basílio C, Arenga M, Marques IB, Perdigão S, Alves I, Santos M, Salgado V, Palos A, Guerreiro R, Isidoro L, Boleixa D, Carneiro P, Neves E, Silva AM, Gonçalves G, Sá MJ.
Mult Scler Relat Disord. 2022 Jul;63:103845. doi: 10.1016/j.msard.2022.103845.
PEDIATRIC NEUROMYELITIS OPTICA SPECTRUM DISORDERS IN PORTUGAL: A MULTICENTRE RETROSPECTIVE STUDY.
Martins C, Moura J, Figueiroa S, Garrido C, Martins J, Samões R, Guimarães J, Melo C, Sousa R, Palavra F, Ferreira J, da Silva AM, Sá MJ, Santos E.
Mult Scler Relat Disord. 2022 Mar;59:103531. doi: 10.1016/j.msard.2022.103531.
SYMPTOMATIC AND RESTORATIVE THERAPIES IN NEUROMYELITIS OPTICA SPECTRUM DISORDERS.
Abboud H, Salazar-Camelo A, George N, Planchon SM, Matiello M, Mealy MA, Goodman A; On-behalf of the Guthy-Jackson Foundation NMO International Clinical Consortium.
J Neurol. 2022 Apr;269(4):1786-1801. doi: 10.1007/s00415-021-10783-4.
NEUROMYELITIS OPTICA SPECTRUM DISORDERS: A NATIONWIDE PORTUGUESE CLINICAL EPIDEMIOLOGICAL STUDY.
Santos E, Rocha AL, Oliveira V, Ferro D, Samões R, Sousa AP, Figueiroa S, Mendonça T, Abreu P, Guimarães J, Sousa R, Melo C, Correia I, Durães J, Sousa L, Ferreira J, de Sá J, Sousa F, Sequeira M, Correia AS, André AL, Basílio C, Arenga M, Mendes I, Marques IB, Perdigão S, Felgueiras H, Alves I, Correia F, Barroso C, Morganho A, Carmona C, Palavra F, Santos M, Salgado V, Palos A, Nzwalo H, Timóteo A, Guerreiro R, Isidoro L, Boleixa D, Carneiro P, Neves E, Silva AM, Gonçalves G, Leite MI, Sá MJ.
Mult Scler Relat Disord. 2021 Nov;56:103258. doi: 10.1016/j.msard.2021.103258.
NEUROMYELITIS OPTICA IN PORTUGAL (NEMIPORT) – A MULTICENTRE STUDY.
Domingos J, Isidoro L, Figueiredo R, Brum M, Capela C, Barros P, Santos E, Macário Mdo C, Pinto Marques J, Pedrosa R, Vale J, Sá MJ.
Clin Neurol Neurosurg. 2015 Jul;134:79-84. doi: 10.1016/j.clineuro.2015.04.001.
PUBLICAÇÕES SOBRE ESCLEROSE MÚLTIPLA 2020 -2024
Publicações sobre EM - 2024
COGNITIVE PHENOTYPES IN PATIENTS WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS WITH DIFFERENT DISEASE DURATION, APPLYING THE INTERNATIONAL CLASSIFICATION OF COGNITIVE DISORDERS IN MS (IC-CODIMS).
Sousa C, Jacques T, França M, Campos P, Sá MJ, Alves RA.
Clin Neuropsychol. 2024 May 7:1-19. doi: 10.1080/13854046.2024.2348831.
ASSESSMENT OF PHONEMIC VERBAL FLUENCY IN PORTUGUESE PATIENTS WITH MULTIPLE SCLEROSIS.
França M, Sousa C, Campos P, Rigueiro-Neves M, Ferreira A, Passos AM, Sá MJ.
J Clin Exp Neuropsychol. 2024 Jul 9:1-9. doi: 10.1080/13803395.2024.2376295.
ROUTINE CSF PARAMETERS AS PREDICTORS OF DISEASE COURSE IN MULTIPLE SCLEROSIS: AN MSBASE COHORT STUDY.
Dekeyser C, Hautekeete M, Cambron M, Van Pesch V, Patti F, Kuhle J, Khoury S, Lechner Scott J, Gerlach O, Lugaresi A, Maimone D, Surcinelli A, Grammond P, Kalincik T, Habek M, Willekens B, Macdonell R, Lalive P, Csepany T, Butzkueven H, Boz C, Tomassini V, Foschi M, Sánchez-Menoyo JL, Altintas A, Mrabet S, Iuliano G, Sa MJ, Alroughani R, Karabudak R, Aguera-Morales E, Gray O, de Gans K, van der Walt A, McCombe PA, Deri N, Garber J, Al-Asmi A, Skibina O, Duquette P, Cartechini E, Spitaleri D, Gouider R, Soysal A, Van Hijfte L, Slee M, Amato MP, Buzzard K, Laureys G.
J Neurol Neurosurg Psychiatry. 2024 Apr 3:jnnp-2023-333307. doi: 10.1136/jnnp-2023-333307.
A MULTI-CENTRE LONGITUDINAL STUDY ANALYSING MULTIPLE SCLEROSIS DISEASE-MODIFYING THERAPY PRESCRIBING PATTERNS DURING THE COVID-19 PANDEMIC.
Lal AP, Foong YC, Sanfilippo PG, Spelman T, Rath L, Levitz D, Fabis-Pedrini M, Foschi M, Habek M, Kalincik T, Roos I, Lechner-Scott J, John N, Soysal A, D’Amico E, Gouider R, Mrabet S, Gross-Paju K, Cárdenas-Robledo S, Moghadasi AN, Sa MJ, Gray O, Oh J, Reddel S, Ramanathan S, Al-Harbi T, Altintas A, Hardy TA, Ozakbas S, Alroughani R, Kermode AG, Surcinelli A, Laureys G, Eichau S, Prat A, Girard M, Duquette P, Hodgkinson S, Ramo-Tello C, Maimone D, McCombe P, Spitaleri D, Sanchez-Menoyo JL, Yetkin MF, Baghbanian SM, Karabudak R, Al-Asmi A, Jakob GB, Khoury SJ, Etemadifar M, van Pesch V, Buzzard K, Taylor B, Butzkueven H, Van der Walt A.
J Neurol. 2024 Jun 27. doi: 10.1007/s00415-024-12518-7.
EXAMINING THE ENVIRONMENTAL RISK FACTORS OF PROGRESSIVE-ONSET AND RELAPSING-ONSET MULTIPLE SCLEROSIS: RECRUITMENT CHALLENGES, POTENTIAL BIAS, AND STATISTICAL STRATEGIES.
Li Y, Saul A, Taylor B, Ponsonby AL, Simpson-Yap S, Blizzard L, Broadley S, Lechner-Scott J; Ausimmune/AusLong Investigators Group; Karabudak R, Patti F, Eichau S, Onofrj M, Ozakbas S, Horakova D, Kubala Havrdova E, Grand’Maison F, Alroughani R, Gerlach O, Amato MP, Altintas A, Girard M, Duquette P, Blanco Y, Ramo-Tello C, Laureys G, Kalincik T, Khoury SJ, Shaygannejad V, Etemadifar M, Singhal B, Mrabet S, Foschi M, Habek M, John N, Hughes S, McCombe P, Ampapa R, van der Walt A, Butzkueven H, de Gans K, McGuigan C, Oreja-Guevara C, Sa MJ, Petersen T, Al-Harbi T, Sempere AP, Van Wijmeersch B, Grigoriadis N, Prevost J, Gray O, Castillo-Triviño T, Macdonell R, Lugaresi A, Sajedi SA; MSBase; van der Mei I.
J Neurol. 2024 Jan;271(1):472-485. doi: 10.1007/s00415-023-11980-z.
DISEASE-MODIFYING THERAPIES IN MANAGING DISABILITY WORSENING IN PAEDIATRIC-ONSET MULTIPLE SCLEROSIS: A LONGITUDINAL ANALYSIS OF GLOBAL AND NATIONAL REGISTRIES.
Sharmin S, Roos I, Malpas CB, Iaffaldano P, Simone M, Filippi M, Kubala Havrdova E, Ozakbas S, Brescia Morra V, Alroughani R, Zaffaroni M, Patti F, Eichau S, Salemi G, Di Sapio A, Inglese M, Portaccio E, Trojano M, Amato MP, Kalincik T; Writing Group; Italian Multiple Sclerosis and Related Disorders Register and MSBase Study Group.
Lancet Child Adolesc Health. 2024 May;8(5):348-357. doi: 10.1016/S2352-4642(24)00047-6.
COMPARING OCRELIZUMAB TO INTERFERON/GLATIRAMER ACETATE IN PEOPLE WITH MULTIPLE SCLEROSIS OVER AGE 60.
Foong YC, Merlo D, Gresle M, Buzzard K, Zhong M, Yeh WZ, Jokubaitis V, Monif M, Skibina O, Ozakbas S, Patti F, Grammond P, Amato MP, Kalincik T, Horakova D, Kubala Havrdova E, Weinstock-Guttman B, Lechner Scott J, Boz C, Sa MJ, Butzkueven H, van der Walt A, Zhu C; MSBASE study group.
J Neurol Neurosurg Psychiatry. 2024 Mar 7:jnnp-2023-332883. doi: 10.1136/jnnp-2023-332883.
Publicações sobre EM - 2023
METABOLIC SYNDROME PARAMETERS AND MULTIPLE SCLEROSIS DISEASE OUTCOMES: A PORTUGUESE CROSS-SECTIONAL STUDY.
Silva AS, Guimarães J, Sousa C, Mendonça L, Soares-Dos-Reis R, Mendonça T, Abreu P, Sequeira L, Sá MJ.
Mult Scler Relat Disord. 2023 Jan;69:104370. doi: 10.1016/j.msard.2022.104370.
CONSENSUS FOR THE EARLY IDENTIFICATION OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS IN PORTUGAL: A DELPHI PANEL.
Sá MJ, Basílio C, Capela C, Cerqueira JJ, Mendes I, Morganho A, Correia de Sá J, Salgado V, Martins Silva A, Vale J, Sousa L.
Acta Med Port. 2023 Mar 1;36(3):167-173. doi: 10.20344/amp.18543.
SAFETY AND EFFECTIVENESS OF CLADRIBINE IN MULTIPLE SCLEROSIS: REAL-WORLD CLINICAL EXPERIENCE FROM 5 TERTIARY HOSPITALS IN PORTUGAL.
Santos M, Sequeira J, Abreu P, Guerreiro R, Santos M, Ferreira J, Brum M, Ladeira F, Leitão L, Dias R, Sá MJ, Salgado V, Capela C, de Sá J.
Clin Neuropharmacol. 2023 May-Jun 01;46(3):105-111. doi: 10.1097/WNF.0000000000000552.
COMPARISON BETWEEN DIMETHYL FUMARATE, FINGOLIMOD, AND OCRELIZUMAB AFTER NATALIZUMAB CESSATION
Zhu C, Kalincik T, Horakova D, Zhou Z, Buzzard K, Skibina O, Alroughani R, Izquierdo G, Eichau S, Kuhle J, Patti F, Grand’Maison F, Hodgkinson S, Grammond P, Lechner-Scott J, Butler E, Prat A, Girard M, Duquette P, Macdonell RAL, Weinstock-Guttman B, Ozakbas S, Slee M, Sa MJ, Van Pesch V, Barnett M, Van Wijmeersch B, Gerlach O, Prevost J, Terzi M, Boz C, Laureys G, Van Hijfte L, Kermode AG, Garber J, Yamout B, Khoury SJ, Merlo D, Monif M, Jokubaitis V, van der Walt A, Butzkueven H; MSBase Study Group.
JAMA Neurol. 2023 Jul 1;80(7):739-748. doi: 10.1001/jamaneurol.2023.1542.
COMPARATIVE EFFECTIVENESS OF AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANT VS FINGOLIMOD, NATALIZUMAB, AND OCRELIZUMAB IN HIGHLY ACTIVE RELAPSING-REMITTING MULTIPLE SCLEROSIS
Kalincik T, Sharmin S, Roos I, Freedman MS, Atkins H, Burman J, Massey J, Sutton I, Withers B, Macdonell R, Grigg A, Torkildsen Ø, Bo L, Lehmann AK, Havrdova EK, Krasulova E, Trnený M, Kozak T, van der Walt A, Butzkueven H, McCombe P, Skibina O, Lechner-Scott J, Willekens B, Cartechini E, Ozakbas S, Alroughani R, Kuhle J, Patti F, Duquette P, Lugaresi A, Khoury SJ, Slee M, Turkoglu R, Hodgkinson S, John N, Maimone D, Sa MJ, van Pesch V, Gerlach O, Laureys G, Van Hijfte L, Karabudak R, Spitaleri D, Csepany T, Gouider R, Castillo-Triviño T, Taylor B, Sharrack B, Snowden JA; MSBase Study Group Collaborators; MSBase Study Group Authors; Mrabet S, Garber J, Sanchez-Menoyo JL, Aguera-Morales E, Blanco Y, Al-Asmi A, Weinstock-Guttman B, Fragoso Y, de Gans K, Kermode A; MSBase Study Group.
JAMA Neurol. 2023 Jul 1;80(7):702-713. doi: 10.1001/jamaneurol.2023.1184.
THE RISK OF SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS IS GEOGRAPHICALLY DETERMINED BUT MODIFIABLE.
Sharmin S, Roos I, Simpson-Yap S, Malpas C, Sánchez MM, Ozakbas S, Horakova D, Havrdova EK, Patti F, Alroughani R, Izquierdo G, Eichau S, Boz C, Zakaria M, Onofrj M, Lugaresi A, Weinstock-Guttman B, Prat A, Girard M, Duquette P, Terzi M, Amato MP, Karabudak R, Grand’Maison F, Khoury SJ, Grammond P, Lechner-Scott J, Buzzard K, Skibina O, van der Walt A, Butzkueven H, Turkoglu R, Altintas A, Maimone D, Kermode A, Shalaby N, Pesch VV, Butler E, Sidhom Y, Gouider R, Mrabet S, Gerlach O, Soysal A, Barnett M, Kuhle J, Hughes S, Sa MJ, Hodgkinson S, Oreja-Guevara C, Ampapa R, Petersen T, Ramo-Tello C, Spitaleri D, McCombe P, Taylor B, Prevost J, Foschi M, Slee M, McGuigan C, Laureys G, Hijfte LV, de Gans K, Solaro C, Oh J, Macdonell R, Aguera-Morales E, Singhal B, Gray O, Garber J, Wijmeersch BV, Simu M, Castillo-Triviño T, Sanchez-Menoyo JL, Khurana D, Al-Asmi A, Al-Harbi T, Deri N, Fragoso Y, Lalive PH, Sinnige LGF, Shaw C, Shuey N, Csepany T, Sempere AP, Moore F, Decoo D, Willekens B, Gobbi C, Massey J, Hardy T, Parratt J, Kalincik T.
Brain. 2023 Nov 2;146(11):4633-4644. doi: 10.1093/brain/awad218.
EFFECTIVENESS OF MULTIPLE DISEASE-MODIFYING THERAPIES IN RELAPSING-REMITTING MULTIPLE SCLEROSIS: CAUSAL INFERENCE TO EMULATE A MULTIARM RANDOMISED TRIAL.
Diouf I, Malpas CB, Sharmin S, Roos I, Horakova D, Kubala Havrdova E, Patti F, Shaygannejad V, Ozakbas S, Eichau S, Onofrj M, Lugaresi A, Alroughani R, Prat A, Duquette P, Terzi M, Boz C, Grand’Maison F, Sola P, Ferraro D, Grammond P, Yamout B, Altintas A, Gerlach O, Lechner-Scott J, Bergamaschi R, Karabudak R, Iuliano G, McGuigan C, Cartechini E, Hughes S, Sa MJ, Solaro C, Kappos L, Hodgkinson S, Slee M, Granella F, de Gans K, McCombe PA, Ampapa R, van der Walt A, Butzkueven H, Sánchez-Menoyo JL, Vucic S, Laureys G, Sidhom Y, Gouider R, Castillo-Trivino T, Gray O, Aguera-Morales E, Al-Asmi A, Shaw C, Al-Harbi TM, Csepany T, Sempere AP, Treviño Frenk I, Stuart EA, Kalincik T.
J Neurol Neurosurg Psychiatry. 2023 Dec;94(12):1004-1011. doi: 10.1136/jnnp-2023-331499.
COMPARATIVE EFFECTIVENESS IN MULTIPLE SCLEROSIS: A METHODOLOGICAL COMPARISON.
Roos I, Diouf I, Sharmin S, Horakova D, Havrdova EK, Patti F, Shaygannejad V, Ozakbas S, Izquierdo G, Eichau S, Onofrj M, Lugaresi A, Alroughani R, Prat A, Girard M, Duquette P, Terzi M, Boz C, Grand’Maison F, Sola P, Ferraro D, Grammond P, Turkoglu R, Buzzard K, Skibina O, Yamou B, Altintas A, Gerlach O, van Pesch V, Blanco Y, Maimone D, Lechner-Scott J, Bergamaschi R, Karabudak R, McGuigan C, Cartechini E, Barnett M, Hughes S, Sa MJ, Solaro C, Ramo-Tello C, Hodgkinson S, Spitaleri D, Soysal A, Petersen T, Granella F, de Gans K, McCombe P, Ampapa R, Van Wijmeersch B, van der Walt A, Butzkueven H, Prevost J, Sanchez-Menoyo JL, Laureys G, Gouider R, Castillo-Triviño T, Gray O, Aguera-Morales E, Al-Asmi A, Shaw C, Deri N, Al-Harbi T, Fragoso Y, Csepany T, Sempere AP, Trevino-Frenk I, Schepel J, Moore F, Malpas C, Kalincik T.
Mult Scler. 2023 Mar;29(3):326-332. doi: 10.1177/13524585231151394.
DISABILITY ACCRUAL IN PRIMARY AND SECONDARY PROGRESSIVE MULTIPLE SCLEROSIS.
Harding-Forrester S, Roos I, Nguyen AL, Malpas CB, Diouf I, Moradi N, Sharmin S, Izquierdo G, Eichau S, Patti F, Horakova D, Kubala Havrdova E, Prat A, Girard M, Duquette P, Grand’Maison F, Onofrj M, Lugaresi A, Grammond P, Ozakbas S, Amato MP, Gerlach O, Sola P, Ferraro D, Buzzard K, Skibina O, Lechner-Scott J, Alroughani R, Boz C, Van Pesch V, Cartechini E, Terzi M, Maimone D, Ramo-Tello C, Yamout B, Khoury SJ, La Spitaleri D, Sa MJ, Blanco Y, Granella F, Slee M, Butler E, Sidhom Y, Gouider R, Bergamaschi R, Karabudak R, Ampapa R, Sánchez-Menoyo JL, Prevost J, Castillo-Trivino T, McCombe PA, Macdonell R, Laureys G, Van Hijfte L, Oh J, Altintas A, de Gans K, Turkoglu R, van der Walt A, Butzkueven H, Vucic S, Barnett M, Cristiano E, Hodgkinson S, Iuliano G, Kappos L, Kuhle J, Shaygannejad V, Soysal A, Weinstock-Guttman B, Van Wijmeersch B, Kalincik T; MSBase investigators.
J Neurol Neurosurg Psychiatry. 2023 Sep;94(9):707-717. doi: 10.1136/jnnp-2022-330726.
PREDICTORS OF TREATMENT SWITCHING IN THE BIG MULTIPLE SCLEROSIS DATA NETWORK.
Spelman T, Magyari M, Butzkueven H, Van Der Walt A, Vukusic S, Trojano M, Iaffaldano P, Horáková D, Drahota J, Pellegrini F, Hyde R, Duquette P, Lechner-Scott J, Sajedi SA, Lalive P, Shaygannejad V, Ozakbas S, Eichau S, Alroughani R, Terzi M, Girard M, Kalincik T, Grand’Maison F, Skibina O, Khoury SJ, Yamout B, Sa MJ, Gerlach O, Blanco Y, Karabudak R, Oreja-Guevara C, Altintas A, Hughes S, McCombe P, Ampapa R, de Gans K, McGuigan C, Soysal A, Prevost J, John N, Inshasi J, Stawiarz L, Manouchehrinia A, Forsberg L, Sellebjerg F, Glaser A, Pontieri L, Joensen H, Rasmussen PV, Sejbaek T, Poulsen MB, Christensen JR, Kant M, Stilund M, Mathiesen H, Hillert J; Big MS Data Network: a collaboration of the Czech MS Registry, the Danish MS Registry, Italian MS Registry, Swedish MS Registry, MSBase Study Group, and OFSEP.
Front Neurol. 2023 Dec 22;14:1274194. doi: 10.3389/fneur.2023.1274194.
EARLY NON-DISABLING RELAPSES ARE IMPORTANT PREDICTORS OF DISABILITY ACCUMULATION IN PEOPLE WITH RELAPSING-REMITTING MULTIPLE SCLEROSIS.
Daruwalla C, Shaygannejad V, Ozakbas S, Havrdova EK, Horakova D, Alroughani R, Boz C, Patti F, Onofrj M, Lugaresi A, Eichau S, Girard M, Prat A, Duquette P, Yamout B, Khoury SJ, Sajedi SA, Turkoglu R, Altintas A, Skibina O, Buzzard K, Grammond P, Karabudak R, van der Walt A, Butzkueven H, Maimone D, Lechner-Scott J, Soysal A, John N, Prevost J, Spitaleri D, Ramo-Tello C, Gerlach O, Iuliano G, Foschi M, Ampapa R, van Pesch V, Barnett M, Shalaby N, D’hooghe M, Kuhle J, Sa MJ, Fabis-Pedrini M, Kermode A, Mrabet S, Gouider R, Hodgkinson S, Laureys G, Van Hijfte L, Macdonell R, Oreja-Guevara C, Cristiano E, McCombe P, Sanchez-Menoyo JL, Singhal B, Blanco Y, Hughes S, Garber J, Solaro C, McGuigan C, Taylor B, de Gans K, Habek M, Al-Asmi A, Mihaela S, Castillo Triviño T, Al-Harbi T, Rojas JI, Gray O, Khurana D, Van Wijmeersch B, Grigoriadis N, Inshasi J, Oh J, Aguera-Morales E, Fragoso Y, Moore F, Shaw C, Baghbanian SM, Shuey N, Willekens B, Hardy TA, Decoo D, Sempere AP, Field D, Wynford-Thomas R, Cunniffe NG, Roos I, Malpas CB, Coles AJ, Kalincik T, Brown JWL.
Mult Scler. 2023 Jun;29(7):875-883. doi: 10.1177/13524585231151951.
VARIABILITY OF THE RESPONSE TO IMMUNOTHERAPY AMONG SUBGROUPS OF PATIENTS WITH MULTIPLE SCLEROSIS.
Diouf I, Malpas CB, Sharmin S, Roos I, Horakova D, Havrdova EK, Patti F, Shaygannejad V, Ozakbas S, Izquierdo G, Eichau S, Onofrj M, Lugaresi A, Alroughani R, Prat A, Girard M, Duquette P, Terzi M, Boz C, Grand’Maison F, Hamdy S, Sola P, Ferraro D, Grammond P, Turkoglu R, Buzzard K, Skibina O, Yamout B, Altintas A, Gerlach O, van Pesch V, Blanco Y, Maimone D, Lechner-Scott J, Bergamaschi R, Karabudak R, Iuliano G, McGuigan C, Cartechini E, Barnett M, Hughes S, Sa MJ, Solaro C, Kappos L, Ramo-Tello C, Cristiano E, Hodgkinson S, Spitaleri D, Soysal A, Petersen T, Slee M, Butler E, Granella F, de Gans K, McCombe P, Ampapa R, Van Wijmeersch B, van der Walt A, Butzkueven H, Prevost J, Sinnige LGF, Sanchez-Menoyo JL, Vucic S, Laureys G, Van Hijfte L, Khurana D, Macdonell R, Gouider R, Castillo-Triviño T, Gray O, Aguera-Morales E, Al-Asmi A, Shaw C, Deri N, Al-Harbi T, Fragoso Y, Csepany T, Perez Sempere A, Trevino-Frenk I, Schepel J, Moore F, Kalincik T.
Eur J Neurol. 2023 Apr;30(4):1014-1024. doi: 10.1111/ene.15706.
HETEROGENEITY ON LONG-TERM DISABILITY TRAJECTORIES IN PATIENTS WITH SECONDARY PROGRESSIVE MS: A LATENT CLASS ANALYSIS FROM BIG MS DATA NETWORK.
Signori A, Lorscheider J, Vukusic S, Trojano M, Iaffaldano P, Hillert J, Hyde R, Pellegrini F, Magyari M, Koch-Henriksen N, Sørensen PS, Spelman T, van der Walt A, Horakova D, Havrdova E, Girard M, Eichau S, Grand’Maison F, Gerlach O, Terzi M, Ozakbas S, Skibina O, Van Pesch V, Sa MJ, Prevost J, Alroughani R, McCombe PA, Gouider R, Mrabet S, Castillo-Trivino T, Zhu C, de Gans K, Sánchez-Menoyo JL, Yamout B, Khoury S, Sormani MP, Kalincik T, Butzkueven H; Big MS Data Network.
J Neurol Neurosurg Psychiatry. 2023 Jan;94(1):23-30. doi: 10.1136/jnnp-2022-329987.
Publicações sobre EM - 2022
COGNITIVE IMPAIRMENT IN MULTIPLE SCLEROSIS PHENOTYPES: NEUROPSYCHOLOGICAL ASSESSMENT IN A PORTUGUESE SAMPLE.
Sousa C, Jacques T, Sá MJ, Alves RA.
Appl Neuropsychol Adult. 2022 Aug 17:1-10. doi: 10.1080/23279095.2022.2112681.
COGNITIVE IMPAIRMENT AND MARKERS OF OPTICAL NEURODEGENERATION IN EARLY MULTIPLE SCLEROSIS.
Silva R, Coelho P, Seabra M, Laranjinha I, Vieira D, Costa O, Jesus J, Fonseca AC, Costa S, Ferreira I, Lemos J, Sousa C, Vale J, Sá MJ, Ruano L.
Neurol Sci. 2022 Jul;43(7):4381-4386. doi: 10.1007/s10072-022-05945-9.
THE SOCIOECONOMIC IMPACT OF MULTIPLE SCLEROSIS IN FRANCE: RESULTS FROM THE PETALS STUDY.
Bouleau A, Dulong C, Schwerer CA, Delgrange R, Bouaou K, Brochu T, Zinai S, Švecová K, Sá MJ, Petropoulos A, Aly S, Labauge P.
Mult Scler J Exp Transl Clin. 2022 Apr 21;8(2):20552173221093219. doi: 10.1177/20552173221093219.
EARLY PREDICTORS OF DISABILITY IN PAEDIATRIC MULTIPLE SCLEROSIS: EVIDENCE FROM A MULTI-NATIONAL REGISTRY.
Sharmin S, Malpas CB, Roos I, Diouf I, Alroughani R, Ozakbas S, Izquierdo G, Eichau S, Horakova D, Havrdova EK, Patti F, Terzi M, Boz C, Yamout B, Khoury SJ, Onofrj M, Lugaresi A, Altintas A, Prat A, Girard M, Duquette P, Sá MJ, La Spitaleri D, Sidhom Y, Gouider R, Mrabet S, Soysal A, Turkoglu R, Amato MP, Fragoso YD, Kalincik T.
J Neurol Neurosurg Psychiatry. 2022 Sep 30:jnnp-2022-329713. doi: 10.1136/jnnp-2022-329713.
MULTIPLE SCLEROSIS SEVERITY SCORE (MSSS) IMPROVES THE ACCURACY OF INDIVIDUALIZED PREDICTION IN MS.
Kalincik T, Kister I, Bacon TE, Malpas CB, Sharmin S, Horakova D, Kubala-Havrdova E, Patti F, Izquierdo G, Eichau S, Ozakbas S, Onofrj M, Lugaresi A, Prat A, Girard M, Duquette P, Grammond P, Sola P, Ferraro D, Alroughani R, Terzi M, Boz C, Grand’Maison F, Bergamaschi R, Gerlach O, Sa MJ, Kappos L, Cartechini E, Lechner-Scott J, van Pesch V, Shaygannejad V, Granella F, Spitaleri D, Iuliano G, Maimone D, Prevost J, Soysal A, Turkoglu R, Ampapa R, Butzkueven H, Cutter G; for MSBase Study Group.
Mult Scler. 2022 Oct;28(11):1752-1761. doi: 10.1177/13524585221084577.
CORRIGENDUM TO LONGITUDINAL MACHINE LEARNING MODELING OF MS PATIENT TRAJECTORIES IMPROVES PREDICTIONS OF DISABILITY PROGRESSION: [COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE, VOLUME 208, (SEPTEMBER 2021) 106180].
De Brouwer E, Becker T, Moreau Y, Havrdova EK, Trojano M, Eichau S, Ozakbas S, Onofrj M, Grammond P, Kuhle J, Kappos L, Sola P, Cartechini E, Lechner-Scott J, Alroughani R, Gerlach O, Kalincik T, Granella F, Grand’Maison F, Bergamaschi R, Sá MJ, Van Wijmeersch B, Soysal A, Sanchez-Menoyo JL, Solaro C, Boz C, Iuliano G, Buzzard K, Aguera-Morales E, Terzi M, Trivio TC, Spitaleri D, Van Pesch V, Shaygannejad V, Moore F, Oreja-Guevara C, Maimone D, Gouider R, Csepany T, Ramo-Tello C, Peeters L.
Comput Methods Programs Biomed. 2022 Jan;213:106479. doi: 10.1016/j.cmpb.2021.106479.
Publicações sobre EM - 2021
NATURAL HISTORY OF RELAPSING REMITTING MULTIPLE SCLEROSIS IN A LONG-LASTING COHORT FROM A TERTIARY MS CENTRE IN PORTUGAL.
Sá MJ, Sequeira L, Ferro D, Marcolino A, Rocha AL, Seabra M, Mendonça T, Abreu P, Guimarães J, Macedo A.
Mult Scler Relat Disord. 2021 Sep;54:103091. doi: 10.1016/j.msard.2021.103091.
ASSESSMENT OF COGNITIVE FUNCTIONS IN PATIENTS WITH MULTIPLE SCLEROSIS APPLYING THE NORMATIVE VALUES OF THE RAO’S BRIEF REPEATABLE BATTERY IN THE PORTUGUESE POPULATION.
Sousa C, Rigueiro-Neves M, Passos AM, Ferreira A, Sá MJ; Group for Validation of the BRBN-T in the Portuguese MS Population.
BMC Neurol. 2021 Apr 21;21(1):170. doi: 10.1186/s12883-021-02193-w.
INFECTIOUS RISK MITIGATION IN PATIENTS WITH MULTIPLE SCLEROSIS UNDER DISEASE-MODIFYING THERAPIES – THE EXPERIENCE OF A COLLABORATIVE NEUROLOGY-INFECTIOUS DISEASES APPROACH.
Ferro D, Prista-Leão B, Costa A, Silva-Pinto A, Abreu C, Sá MJ.
J Cent Nerv Syst Dis. 2021 Sep 8;13:11795735211042188. doi: 10.1177/11795735211042188.
MULTIPLE SCLEROSIS, DISEASE-MODIFYING THERAPIES AND COVID-19: A SYSTEMATIC REVIEW ON IMMUNE RESPONSE AND VACCINATION RECOMMENDATIONS.
Cabreira V, Abreu P, Soares-Dos-Reis R, Guimarães J, Sá MJ.
Vaccines (Basel). 2021 Jul 11;9(7):773. doi: 10.3390/vaccines9070773.
DEFINING THE PRODROMAL PHASE OF MULTIPLE SCLEROSIS BASED ON HEALTHCARE ACCESS IN A PORTUGUESE POPULATION – PRODMS STUDY.
Jorge A, André A, Rocha AL, Figueiredo C, Santos M, Freitas E, Sousa L, Shamasna M, Salgado V, de Sá J, Cerqueira J, Vale J, Sá MJ, Correia I.
Mult Scler Relat Disord. 2021 Oct;55:103154. doi: 10.1016/j.msard.2021.103154.
RISCOP-COGNITIVE PROFILE IN A PORTUGUESE COHORT OF RADIOLOGICAL ISOLATED SYNDROME PATIENTS: A CASE-CONTROL STUDY.
Carvalho V, Soares C, Gomes I, Carvalho A, Serrazina F, Rodrigues SG, Pinheiro J, Marques IB, Correia F, Correia AS, de Sá J, Sousa L, Vale J, Sá MJ, Sousa C, Ferreira J.
Mult Scler Relat Disord. 2021 May;50:102832. doi: 10.1016/j.msard.2021.102832.
THERAPEUTIC INERTIA IN RELAPSING-REMITTING MULTIPLE SCLEROSIS.
Rodrigues R, Rocha R, Bonifácio G, Ferro D, Sabença F, Gonçalves AI, Correia F, Pinheiro J, Loureiro JL, Guerreiro RP, Vale J, Sá MJ, Costa A.
Mult Scler Relat Disord. 2021 Oct;55:103176. doi: 10.1016/j.msard.2021.103176.
TYPED STUDY: NATALIZUMAB FOR THE TREATMENT OF PEDIATRIC-ONSET MULTIPLE SCLEROSIS IN PORTUGAL.
Palavra F, Figueiroa S, Correia AS, Tapadinhas F, Cerqueira J, Guerreiro RP, de Sá J, Sá MJ, Almeida S, Mota P, Sousa L.
Mult Scler Relat Disord. 2021 Jun;51:102865. doi: 10.1016/j.msard.2021.102865.
DETERMINANTS OF THERAPEUTIC LAG IN MULTIPLE SCLEROSIS.
Roos I, Leray E, Frascoli F, Casey R, Brown JWL, Horakova D, Havrdova EK, Debouverie M, Trojano M, Patti F, Izquierdo G, Eichau S, Edan G, Prat A, Girard M, Duquette P, Onofrj M, Lugaresi A, Grammond P, Ciron J, Ruet A, Ozakbas S, De Seze J, Louapre C, Zephir H, Sá MJ, Sola P, Ferraro D, Labauge P, Defer G, Bergamaschi R, Lebrun-Frenay C, Boz C, Cartechini E, Moreau T, Laplaud D, Lechner-Scott J, Grand’Maison F, Gerlach O, Terzi M, Granella F, Alroughani R, Iuliano G, Van Pesch V, Van Wijmeersch B, Spitaleri D, Soysal A, Berger E, Prevost J, Aguera-Morales E, McCombe P, Castillo Triviño T, Clavelou P, Pelletier J, Turkoglu R, Stankoff B, Gout O, Thouvenot E, Heinzlef O, Sidhom Y, Gouider R, Csepany T, Bourre B, Al Khedr A, Casez O, Cabre P, Montcuquet A, Wahab A, Camdessanche JP, Maurousset A, Patry I, Hankiewicz K, Pottier C, Maubeuge N, Labeyrie C, Nifle C, Coles A, Malpas CB, Vukusic S, Butzkueven H, Kalincik T.
Mult Scler. 2021 Oct;27(12):1838-1851. doi: 10.1177/1352458520981300.
NATALIZUMAB, FINGOLIMOD AND DIMETHYL FUMARATE USE AND PREGNANCY-RELATED RELAPSE AND DISABILITY IN WOMEN WITH MULTIPLE SCLEROSIS.
Yeh WZ, Widyastuti PA, Van der Walt A, Stankovich J, Havrdova E, Horakova D, Vodehnalova K, Ozakbas S, Eichau S, Duquette P, Kalincik T, Patti F, Boz C, Terzi M, Yamout BI, Lechner-Scott J, Sola P, Skibina OG, Barnett M, Onofrj M, Sá MJ, McCombe PA, Grammond P, Ampapa R, Grand’Maison F, Bergamaschi R, Spitaleri DLA, Van Pesch V, Cartechini E, Hodgkinson S, Soysal A, Saiz A, Gresle M, Uher T, Maimone D, Turkoglu R, Hupperts RM, Amato MP, Granella F, Oreja-Guevara C, Altintas A, Macdonell RA, Castillo-Trivino T, Butzkueven H, Alroughani R, Jokubaitis VG; MSBase Study Group.
Neurology. 2021 Jun 15;96(24):e2989-e3002. doi: 10.1212/WNL.0000000000012084.
Publicações sobre EM - 2020
STATE OF THE ART AND FUTURE CHALLENGES IN MULTIPLE SCLEROSIS RESEARCH AND MEDICAL MANAGEMENT: AN INSIGHT INTO THE 5TH INTERNATIONAL PORTO CONGRESS OF MULTIPLE SCLEROSIS.
Sá MJ, Soares Dos Reis R, Altintas A, Celius EG, Chien C, Comi G, Graus F, Hillert J, Hobart J, Khan G, Kissani N, Langdon D, Leite MI, Okuda DT, Palace J, Papais-Alvarenga RM, Mendes-Pinto I, Shi FD.
Neurol Ther. 2020 Dec;9(2):281-300. doi: 10.1007/s40120-020-00202-7.
THE EPIDEMIOLOGY OF MULTIPLE SCLEROSIS IN THE ENTRE DOURO E VOUGA REGION OF NORTHERN PORTUGAL: A MULTISOURCE POPULATION-BASED STUDY.
Branco M, Alves I, Martins da Silva A, Pinheiro J, Sá MJ, Correia I, Sousa L, Brandão E, Veira C, Gomes B, Ruano L.
BMC Neurol. 2020 May 19;20(1):195. doi: 10.1186/s12883-020-01755-8.
TRENDS IN HOSPITAL READMISSIONS IN MULTIPLE SCLEROSIS PATIENTS BETWEEN 2009 AND 2015.
Cabreira V, Abreu P, Maia C, Costa A, Sá MJ.
Mult Scler Relat Disord. 2020 Oct;45:102396. doi: 10.1016/j.msard.2020.102396.
[RECOMMENDATIONS ABOUT MULTIPLE SCLEROSIS MANAGEMENT DURING PREGNANCY, PARTUM AND POST-PARTUM: CONSENSUS POSITION OF THE PORTUGUESE MULTIPLE SCLEROSIS STUDY GROUP].
Batista S, Martins da Silva A, Sá MJ, Sousa L, De Sá J, Pedrosa R, Cerqueira J, Pinheiro J, Abreu P, Simões RM, Vale J.
Acta Med Port. 2020 Sep 1;33(9):611-621. doi: 10.20344/amp.12777.
LONG-TERM SAFETY AND EFFECTIVENESS OF NATALIZUMAB TREATMENT IN CLINICAL PRACTICE: 10 YEARS OF REAL-WORLD DATA FROM THE TYSABRI OBSERVATIONAL PROGRAM (TOP)
Butzkueven H, Kappos L, Wiendl H, Trojano M, Spelman T, Chang I, Kasliwal R, Jaitly S, Campbell N, Ho PR, Licata S; Tysabri Observational Program (TOP) Investigators.
J Neurol Neurosurg Psychiatry. 2020 Jun;91(6):660-668. doi: 10.1136/jnnp-2019-322326
DELAY FROM TREATMENT START TO FULL EFFECT OF IMMUNOTHERAPIES FOR MULTIPLE SCLEROSIS.
Roos I, Leray E, Frascoli F, Casey R, Brown JWL, Horakova D, Havrdova EK, Trojano M, Patti F, Izquierdo G, Eichau S, Onofrj M, Lugaresi A, Prat A, Girard M, Grammond P, Sola P, Ferraro D, Ozakbas S, Bergamaschi R, Sá MJ, Cartechini E, Boz C, Granella F, Hupperts R, Terzi M, Lechner-Scott J, Spitaleri D, Van Pesch V, Soysal A, Olascoaga J, Prevost J, Aguera-Morales E, Slee M, Csepany T, Turkoglu R, Sidhom Y, Gouider R, Van Wijmeersch B, McCombe P, Macdonell R, Coles A, Malpas CB, Butzkueven H, Vukusic S, Kalincik T; MSBase; OFSEP investigators.
Brain. 2020 Sep 1;143(9):2742-2756. doi: 10.1093/brain/awaa231.